NeoRx makes $7 million private placement

Article

Monoclonal antibody agent developer NeoRx has completed a privateplacement of equity to institutional investors in a deal worth$7 million to the Seattle-based firm. The company will use thefunds to pursue continued clinical trials of its Biostent

Monoclonal antibody agent developer NeoRx has completed a privateplacement of equity to institutional investors in a deal worth$7 million to the Seattle-based firm. The company will use thefunds to pursue continued clinical trials of its Biostent andAvicidin therapy agents, according to president and CEO Dr. PaulAbrams.

NeoRx is awaiting final word from the Food and Drug Administrationon its Verluma agent for imaging small-cell lung cancer. An FDApanel recommended Verluma for approval in December (SCAN 12/27/95).NeoRx will receive $4.5 million from Verluma licensee Du PontMerck Pharmaceutical when the product is approved.

Recent Videos
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Can AI Assessment of Longitudinal MRI Scans Improve Prediction for Pediatric Glioma Recurrence?
A Closer Look at MRI-Guided Adaptive Radiotherapy for Monitoring and Treating Glioblastomas
Incorporating CT Colonography into Radiology Practice
What New Research Reveals About Computed Tomography and Radiation-Induced Cancer Risk
What New Interventional Radiology Research Reveals About Treatment for Breast Cancer Liver Metastases
New Mammography Studies Assess Image-Based AI Risk Models and Breast Arterial Calcification Detection
Can Deep Learning Provide a CT-Less Alternative for Attenuation Compensation with SPECT MPI?
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Related Content
© 2025 MJH Life Sciences

All rights reserved.